Sunshine Biopharma Inc.

Sunshine Biopharma is a pharmaceutical company that researches and offers medicines in therapeutic areas such as oncology and antivirals. The company operates through two wholly-owned Canadian subsidiaries. Nora Pharma Inc. currently markets 71 generic prescription drugs in Canada. Sunshine Biopharma Canada Inc. develops and sells over-the-counter (OTC) supplements. Sunshine Biopharma is also advancing a proprietary drug development program. This includes K1.1 mRNA, an LNP encapsulated mRNA designed to target liver cancer, and SBFM-PL4, a protease inhibitor intended for the treatment of SARS Coronavirus infections. The company's commercial operations focus on acquiring rights to pharmaceutical products for sale, primarily in Canada and with a goal for global expansion. These rights are secured through strategic arrangements. Under In-licensing and Supply Agreements, Nora Pharma acquires rights to import, market, sell, and distribute products in Canada by purchasing drug dossiers from strategic partners. Nora Pharma then files these dossiers with Health Canada for regulatory approval, a process that takes an average of 12 months, and sells the products under the Nora Pharma label. Through Cross-licensing, Nora Pharma obtains rights to import, market, sell, and distribute products in Canada via authorization letters from pharmaceutical partners whose products are already approved in Canada. Nora Pharma still requires its own Health Canada approval, which averages 45-60 days, and sells these products under its own label. Lastly, Distribution Agreements allow Nora Pharma to market, sell, and distribute products in Canada by signing agreements with pharmaceutical partners whose products are already Health Canada approved, with these products sold under the partners' label. Generic drugs are pharmaceutically equivalent to brand-name drugs, containing identical medicinal ingredients in the same amounts.